Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors.

Kidd AC, McGettrick M, Tsim S, Halligan DL, Bylesjo M, Blyth KG.

BMJ Open Respir Res. 2018 Jan 30;5(1):e000240. doi: 10.1136/bmjresp-2017-000240. eCollection 2018.

2.

Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma.

Zhou JG, Zhong H, Zhang J, Jin SH, Roudi R, Ma H.

Front Oncol. 2019 Feb 15;9:78. doi: 10.3389/fonc.2019.00078. eCollection 2019.

3.

Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.

Kircheva DY, Husain AN, Watson S, Kindler HL, Durkin A, Vigneswaran WT.

Eur J Cardiothorac Surg. 2016 Jun;49(6):1642-7. doi: 10.1093/ejcts/ezv422. Epub 2016 Jan 21.

PMID:
26802143
4.

Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.

Billé A, Krug LM, Woo KM, Rusch VW, Zauderer MG.

J Thorac Oncol. 2016 Feb;11(2):249-55. doi: 10.1016/j.jtho.2015.10.003. Epub 2015 Dec 10.

5.

Inflammation-based prognostic indices in malignant pleural mesothelioma.

Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, Sharma R.

J Thorac Oncol. 2012 Mar;7(3):587-94. doi: 10.1097/JTO.0b013e31823f45c1.

6.

A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis.

Brims FJ, Meniawy TM, Duffus I, de Fonseka D, Segal A, Creaney J, Maskell N, Lake RA, de Klerk N, Nowak AK.

J Thorac Oncol. 2016 Apr;11(4):573-82. doi: 10.1016/j.jtho.2015.12.108. Epub 2016 Jan 8.

7.

Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.

Yamagishi T, Fujimoto N, Nishi H, Miyamoto Y, Hara N, Asano M, Fuchimoto Y, Wada S, Kitamura K, Ozaki S, Kishimoto T.

Lung Cancer. 2015 Oct;90(1):111-7. doi: 10.1016/j.lungcan.2015.07.014. Epub 2015 Jul 30.

PMID:
26259877
8.

Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.

Hasan B, Greillier L, Pallis A, Menis J, Gaafar R, Sylvester R, Fennell DA, Baas P, Surmont V, Van Meerbeeck JP, O'brien ME.

Eur J Cancer. 2014 Nov;50(16):2771-82. doi: 10.1016/j.ejca.2014.07.020. Epub 2014 Aug 21.

PMID:
25155251
9.

Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.

Ghanim B, Klikovits T, Hoda MA, Lang G, Szirtes I, Setinek U, Rozsas A, Renyi-Vamos F, Laszlo V, Grusch M, Filipits M, Scheed A, Jakopovic M, Samarzija M, Brcic L, Stancic-Rokotov D, Kern I, Rozman A, Dekan G, Klepetko W, Berger W, Glasz T, Dome B, Hegedus B.

Br J Cancer. 2015 Mar 3;112(5):783-92. doi: 10.1038/bjc.2015.9. Epub 2015 Jan 29.

10.

Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.

Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T.

J Thorac Oncol. 2008 Nov;3(11):1317-24. doi: 10.1097/JTO.0b013e318187491c.

11.

Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.

Rena O, Boldorini R, Papalia E, Mezzapelle R, Baietto G, Roncon A, Casadio C.

Ann Thorac Surg. 2015 Apr;99(4):1177-83. doi: 10.1016/j.athoracsur.2014.11.050. Epub 2015 Feb 7.

PMID:
25669666
12.

Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.

Blayney JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Mutti L, O'Byrne KJ, Scullin P, Gaafar R, Baas P, Van Meerbeeck J, Fennell DA.

Eur J Cancer. 2012 Nov;48(16):2983-92. doi: 10.1016/j.ejca.2012.05.018. Epub 2012 Jun 15.

PMID:
22704893
13.

MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.

Kirschner MB, Cheng YY, Armstrong NJ, Lin RC, Kao SC, Linton A, Klebe S, McCaughan BC, van Zandwijk N, Reid G.

Mol Oncol. 2015 Mar;9(3):715-26. doi: 10.1016/j.molonc.2014.11.007. Epub 2014 Dec 2.

14.

The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma.

Pinato DJ, Mauri FA, Lloyd T, Vaira V, Casadio C, Boldorini RL, Sharma R.

Br J Cancer. 2013 Feb 19;108(3):621-8. doi: 10.1038/bjc.2013.9. Epub 2013 Jan 29.

15.

Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).

Yoneda K, Tanaka F, Kondo N, Orui H, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Tsubota N, Sato A, Tsujimura T, Kuribayashi K, Fukuoka K, Nakano T, Hasegawa S.

Ann Surg Oncol. 2012 Dec;19(13):4229-37. doi: 10.1245/s10434-012-2506-0. Epub 2012 Jul 24.

PMID:
22825770
16.

Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.

Cedrés S, Montero MA, Zamora E, Martínez A, Martínez P, Fariñas L, Navarro A, Torrejon D, Gabaldon A, Ramon Y Cajal S, Felip E.

Clin Transl Oncol. 2014 Sep;16(9):776-82. doi: 10.1007/s12094-013-1146-6. Epub 2013 Dec 10.

PMID:
24323466
17.

Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database.

Klikovits T, Hoda MA, Dong Y, Arns M, Baumgartner B, Errhalt P, Geltner C, Machan B, Pohl W, Hutter J, Eckmayr J, Studnicka M, Flicker M, Cerkl P, Kirchbacher K, Klepetko W.

Wien Klin Wochenschr. 2016 Sep;128(17-18):627-34. doi: 10.1007/s00508-016-1037-2. Epub 2016 Jul 25.

18.

Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.

Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N.

Br J Cancer. 2014 Oct 28;111(9):1860-9. doi: 10.1038/bjc.2014.478. Epub 2014 Sep 4.

19.

Validation of genomics-based prognostic tests in malignant pleural mesothelioma.

Gordon GJ, Rockwell GN, Godfrey PA, Jensen RV, Glickman JN, Yeap BY, Richards WG, Sugarbaker DJ, Bueno R.

Clin Cancer Res. 2005 Jun 15;11(12):4406-14.

20.

Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.

Nakas A, Waller D.

Eur J Cardiothorac Surg. 2014 Sep;46(3):380-5; discussion 385. doi: 10.1093/ejcts/ezt664. Epub 2014 Jan 30.

PMID:
24482386

Supplemental Content

Support Center